The poorly immunogenic tumor microenvironment of pancreatic cancer: the impact of radiation therapy, and strategies targeting resistance.
PDAC
SBRT
immunotherapy
lymphoid cells
myeloid cells
pancreatic cancer
radiation therapy
tumor microenvironment
Journal
Immunotherapy
ISSN: 1750-7448
Titre abrégé: Immunotherapy
Pays: England
ID NLM: 101485158
Informations de publication
Date de publication:
12 2022
12 2022
Historique:
pubmed:
6
12
2022
medline:
16
12
2022
entrez:
5
12
2022
Statut:
ppublish
Résumé
Pancreatic cancer is one of the most lethal cancers, due to its uniquely aggressive behavior and resistance to therapy. The tumor microenvironment of pancreatic cancer is immunosuppressive, and attempts at utilizing immunotherapies have been unsuccessful. Radiation therapy (RT) results in immune activation and antigen presentation in other cancers, but in pancreatic cancer has had limited success in stimulating immune responses. RT activates common pathways of fibrosis and chronic inflammation seen in pancreatic cancer, resulting in immune suppression. Here we describe the pancreatic tumor microenvironment with regard to fibrosis, myeloid and lymphoid cells, and the impact of RT. We also describe strategies of targeting these pathways that have promise to improve outcomes by harnessing the cytotoxic and immune-activating aspects of RT.
Identifiants
pubmed: 36468417
doi: 10.2217/imt-2022-0046
doi:
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM